03.07.2023 14:50:02

Coherus Rolls Out YUSIMRY At $995 Per Carton In US

(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

The pricing represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

YUSIMRY is presented in a state-of-the-art autoinjector and includes Coherus' proprietary non-stinging, citrate-free formulation and a 29-gauge needle.

YUSIMRY, approved in 2021 by the U.S. Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

YUSIMRY Solutions - Coherus' patient services platform - will ensure improved access and a fast and seamless experience as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.

Analysen zu Coherus BioSciences Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Coherus BioSciences Inc 1,52 5,60% Coherus BioSciences Inc